These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27456203)

  • 1. Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.
    Barabas AZ; Cole CD; Graeff RM; Lafreniere R; Weir DM
    Immunol Res; 2017 Feb; 65(1):402-409. PubMed ID: 27456203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique.
    Barabas AZ; Cole CD; Barabas AD; Graeff RM; Lafreniere R; Weir DM
    Autoimmun Rev; 2009 Jun; 8(7):552-7. PubMed ID: 19393215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-initiated beneficial and harmful immune responses.
    Barabas AZ; Cole CD; Lafreniere R
    Immunol Res; 2018 Dec; 66(6):783-789. PubMed ID: 30456543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders.
    Barabas AZ; Cole CD; Barabas AD; Graeff RM; Lafreniere R; Weir DM
    Scand J Immunol; 2010 Mar; 71(3):125-33. PubMed ID: 20415778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The modified vaccination technique designed to prevent and cure acute and chronic disorders.
    Barabas AZ; Cole CD; Kovacs ZB; Kovacs EI; Lafreniere R; Weir DM
    Hum Antibodies; 2020; 28(2):111-121. PubMed ID: 31594214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Lafreniere R; Weir DM
    Autoimmunity; 2012 Nov; 45(7):495-509. PubMed ID: 22816962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Biologics; 2007 Mar; 1(1):59-68. PubMed ID: 19707349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Ann N Y Acad Sci; 2007 Sep; 1110():619-29. PubMed ID: 17911477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated antibody response by antigen presentation in immune complexes.
    Barabas AZ; Cole CD; Kovacs ZB; Lafreniere R
    Med Sci Monit; 2007 May; 13(5):BR119-24. PubMed ID: 17476190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen.
    Barabas AZ; Cole CD; Graeff RM; Morcol T; Lafreniere R
    Hum Antibodies; 2016; 24(3-4):45-51. PubMed ID: 28128764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of autoimmunologists in investigating and treating autoimmune disorders.
    Barabas AZ; Cole CD; Graeff RM; Lafreniere R; Weir DM
    Autoimmun Rev; 2011 Jan; 10(3):166-70. PubMed ID: 20887816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New vaccination technology for endogenous antigen-derived ailments.
    Barabas AZ; Cole CD; Barabas AD; Bahlis NJ; Lafreniere R
    IDrugs; 2008 Feb; 11(2):111-5. PubMed ID: 18240096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and spectrum of autoimmunity.
    Perl A
    Methods Mol Biol; 2012; 900():1-9. PubMed ID: 22933062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of human autoimmunity--autoantibodies versus autoimmune disease.
    Lleo A; Invernizzi P; Gao B; Podda M; Gershwin ME
    Autoimmun Rev; 2010 Mar; 9(5):A259-66. PubMed ID: 19963079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regaining tolerance to a self-antigen by the modified vaccination technique.
    Barabas AZ; Cole CD; Lafreniere R; Weir DM
    Clin Rev Allergy Immunol; 2013 Oct; 45(2):193-201. PubMed ID: 23296949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid induction of autoantibodies by endogenous ovarian antigens and activated T cells: implication in autoimmune disease pathogenesis and B cell tolerance.
    Lou YH; McElveen MF; Garza KM; Tung KS
    J Immunol; 1996 May; 156(9):3535-40. PubMed ID: 8617983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols.
    Gregerson DS; Obritsch WF; Donoso LA
    J Immunol; 1993 Nov; 151(10):5751-61. PubMed ID: 7693817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between food antigens and the immune system: Association with autoimmune disorders.
    Vojdani A; Gushgari LR; Vojdani E
    Autoimmun Rev; 2020 Mar; 19(3):102459. PubMed ID: 31917265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the thymus in the integrated evolution of the recombinase-dependent adaptive immune response and the neuroendocrine system.
    Mottet M; Goffinet L; Beckers A; Bodart G; Morrhaye G; Kermani H; Renard C; Martens H; Geenen V
    Neuroimmunomodulation; 2011; 18(5):314-9. PubMed ID: 21952683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit.
    Sun JB; Czerkinsky C; Holmgren J
    Scand J Immunol; 2010 Jan; 71(1):1-11. PubMed ID: 20017804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.